Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Phenotypic drug discovery (PDD) screens compounds in cellular models that represent disease-relevant phenotypes, offering a compelling alternative to traditional target-based approaches. Unlike conventional methods, where compounds act on a single predefined target, PDD identifies compounds capable of exerting therapeutic effects through multiple targets and mechanisms. This makes PDD particularly valuable for discovering first-in-class drugs, especially for diseases with poorly understood molecular mechanisms or those lacking validated therapeutic targets. By enabling broader exploration of biological systems and uncovering multi-target drugs (polypharmacology), PDD provides a powerful strategy for tackling complex diseases. In this study, we introduce PhenoScreen, a deep learning framework designed to advance PDD by utilizing large-scale compound-phenotype association data. Through contrastive learning, PhenoScreen connects chemical space with cellular morphological profiles, allowing for accurate prediction of compound-induced phenotypic changes. PhenoScreen can also accurately identfiy lead compounds which could induce user defined phenotypic shift but more novel scaffolds using different levels of phenotypic information reflected by diverse compounds. The model was validated across multiple screening tasks and successfully predicted active compounds inducing user-specified phenotypes with varying inhibitory effects in the osteosarcoma phenotypic model. Further, other than showing effectiveness to osteosarcoma, our experiments also showed that PhenoScreen demonstrated strong generalization to rhabdomyosarcoma, and the active compound we screened had an IC50 of up to 6.62 uM, suggesting its ability to capture key phenotypic features shared across cancer cells. These results underscore PhenoScreen's potential to accelerate drug discovery by identifying novel therapeutic pathways and increasing the diversity of viable drug candidates. PhenoScreen is accessible online via our group's web server for compound virtual screening at https://bailab.siais.shanghaitech.edu.cn/services/PhenoScreen/, and the source codes are available at https://github.com/Shihang-Wang-58/PhenoScreen.
Phenotypic drug discovery (PDD) screens compounds in cellular models that represent disease-relevant phenotypes, offering a compelling alternative to traditional target-based approaches. Unlike conventional methods, where compounds act on a single predefined target, PDD identifies compounds capable of exerting therapeutic effects through multiple targets and mechanisms. This makes PDD particularly valuable for discovering first-in-class drugs, especially for diseases with poorly understood molecular mechanisms or those lacking validated therapeutic targets. By enabling broader exploration of biological systems and uncovering multi-target drugs (polypharmacology), PDD provides a powerful strategy for tackling complex diseases. In this study, we introduce PhenoScreen, a deep learning framework designed to advance PDD by utilizing large-scale compound-phenotype association data. Through contrastive learning, PhenoScreen connects chemical space with cellular morphological profiles, allowing for accurate prediction of compound-induced phenotypic changes. PhenoScreen can also accurately identfiy lead compounds which could induce user defined phenotypic shift but more novel scaffolds using different levels of phenotypic information reflected by diverse compounds. The model was validated across multiple screening tasks and successfully predicted active compounds inducing user-specified phenotypes with varying inhibitory effects in the osteosarcoma phenotypic model. Further, other than showing effectiveness to osteosarcoma, our experiments also showed that PhenoScreen demonstrated strong generalization to rhabdomyosarcoma, and the active compound we screened had an IC50 of up to 6.62 uM, suggesting its ability to capture key phenotypic features shared across cancer cells. These results underscore PhenoScreen's potential to accelerate drug discovery by identifying novel therapeutic pathways and increasing the diversity of viable drug candidates. PhenoScreen is accessible online via our group's web server for compound virtual screening at https://bailab.siais.shanghaitech.edu.cn/services/PhenoScreen/, and the source codes are available at https://github.com/Shihang-Wang-58/PhenoScreen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.